MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $1.14B
• Dividend Yield: N/A
• Average Volume (3M): 830.42K
• Price to Earnings (P/E): 28.2
• Beta (1Y): 0.84
• Revenue Growth: 14.77%
• EPS Growth: -58.90%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 148,102,160
• 10 Day Avg. Volume: 1,257,155
• 30 Day Avg. Volume: 830,421
• PEG Ratio: -0.84
• Price to Book (P/B): 7.32
• Price to Sales (P/S): 4.05
• P/FCF Ratio: 21.92
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 2.34
• Enterprise Value/Gross Profit: 2.86
• Enterprise Value/Ebitda: 13.15
• 1Y Price Target: $12.00
• Price Target Upside: 77.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: $7.50 ▲(11.11% Upside)

MiMedx Group's strong financial performance and positive earnings call are the primary drivers of its stock score. The company shows robust revenue growth and cash generation, with a positive outlook for the year. However, technical indicators suggest a bearish trend, and valuation metrics indicate moderate pricing. Potential challenges include Medicare reimbursement reforms and legal expenses.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for MiMedx's products, enhancing its market position and supporting long-term financial stability.

Cash Generation

Strong cash generation provides MiMedx with financial flexibility to invest in growth opportunities and withstand market fluctuations.

Product Efficacy

Demonstrated product efficacy strengthens MiMedx's competitive advantage, potentially increasing market share and supporting long-term growth.

Negative Factors

Medicare Reimbursement Uncertainty

Uncertainty around Medicare reforms could affect revenue streams and profitability, posing a risk to MiMedx's financial performance.

Legal and Regulatory Expenses

Ongoing legal expenses can strain financial resources and distract management, potentially impacting operational efficiency and profitability.

Profit Margin Decline

Declining profit margins may indicate rising costs or pricing pressures, which could challenge MiMedx's ability to maintain profitability.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. (MDXG) is a biotechnology company specializing in regenerative medicine and wound care products derived from human placental tissue. The company focuses on developing and commercializing innovative solutions for the treatment of chronic and acute wounds, surgical wounds, and orthopedic conditions. MiMedx's core offerings include allograft tissue products, which are used to promote healing and tissue regeneration, primarily in the fields of orthopedics, wound care, and surgical applications.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its allograft tissue products. The company sells these products to hospitals, outpatient surgical centers, and other healthcare providers. Revenue streams are largely derived from the distribution of its advanced wound care and orthopedic solutions, with a significant emphasis on the management of chronic wounds such as diabetic foot ulcers and venous leg ulcers. MiMedx has established partnerships with various healthcare organizations and distributors, which enhance its market reach and customer base. The company's financial performance is also influenced by trends in healthcare spending, the adoption of regenerative medicine, and the regulatory environment surrounding tissue-based therapies.

MiMedx Group Financial Statement Overview

Summary

MiMedx Group demonstrates a solid financial position with consistent revenue growth and strong cash flow generation. The company has improved its balance sheet by reducing leverage and increasing equity. However, declining profit margins and past financial instability highlight areas for potential improvement.

Income Statement

MiMedx Group has shown consistent revenue growth, with a notable 8.16% increase in the TTM period. The gross profit margin remains strong at 81.99%, indicating efficient cost management. However, the net profit margin has decreased from 12.16% in 2024 to 10.38% in the TTM, suggesting some pressure on profitability. The EBIT and EBITDA margins have also declined, reflecting potential operational challenges.

Balance Sheet

The company's debt-to-equity ratio has improved significantly, dropping to 0.0057 in the TTM, indicating a strong equity position and reduced leverage. Return on equity is robust at 19.18%, although it has decreased from previous years. The equity ratio stands at 74.86%, showcasing a solid capital structure. However, past periods of negative equity and high leverage pose a risk if financial conditions change.

Cash Flow

MiMedx Group's cash flow performance is strong, with a 10.58% growth in free cash flow in the TTM. The operating cash flow to net income ratio is healthy at 1.18, indicating efficient cash generation relative to profits. The free cash flow to net income ratio is stable at 1.0, suggesting that the company effectively converts its earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	393.44M	348.88M	321.48M	267.84M	242.02M	248.23M
Gross Profit	322.57M	288.81M	266.84M	219.53M	202.39M	208.90M
EBITDA	70.05M	65.35M	40.54M	-10.68M	-1.89M	-37.52M
Net Income	40.83M	42.42M	67.44M	-30.20M	-12.30M	-49.28M
Balance Sheet
Total Assets	318.99M	263.92M	239.05M	171.43M	187.93M	202.03M
Cash, Cash Equivalents and Short-Term Investments	142.08M	104.42M	82.00M	65.95M	87.08M	95.81M
Total Debt	1.38M	24.84M	48.10M	52.47M	53.29M	51.83M
Total Liabilities	80.04M	70.81M	96.33M	96.92M	95.35M	110.61M
Stockholders Equity	238.95M	193.11M	142.72M	74.51M	92.58M	91.42M
Cash Flow
Free Cash Flow	63.53M	64.52M	24.79M	-19.41M	-5.20M	-34.49M
Operating Cash Flow	67.83M	66.20M	26.77M	-17.89M	-1.98M	-30.26M
Investing Cash Flow	-9.32M	-9.58M	-2.15M	-2.66M	-3.40M	-4.55M
Financing Cash Flow	-5.23M	-34.20M	-8.57M	-580.00K	-3.35M	61.56M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 6.75 is below the 20-day moving average (MA) of 7.25, below the 50-day MA of 7.05, and below the 200-day MA of 7.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.84 is Neutral, neither overbought nor oversold. The STOCH value of 6.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	72 Outperform	$1.14B	28.17	19.44%	―	14.77%	-58.90%
PHAR	70 Outperform	$1.16B	1,223.61	0.44%	―	26.54%	―
MAZE	59 Neutral	$1.71B	―	-36.13%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORIC	43 Neutral	$1.17B	―	-39.73%	―	―	4.29%
ATAI	38 Underperform	$1.44B	―	―	―	―	―

MiMedx Group Corporate Events

MiMedx Group Inc. Reports Record Q3 Revenue

MiMedx Group Inc. recently held its earnings call for the third quarter, showcasing a strong performance with record revenue and substantial growth in key business areas. Despite the positive results, the company acknowledged potential challenges due to upcoming Medicare reimbursement reforms and ongoing legal expenses. However, MiMedx expressed confidence in its ability to navigate these uncertainties and continue its growth trajectory.

MiMedx Group Reports Strong Q3 2025 Financial Results

MiMedx Group Inc., a leader in the healthcare sector, specializes in providing innovative solutions for wound care, burn, and surgical applications. The company recently reported its financial performance for the third quarter of 2025, highlighting a significant increase in net sales and net income compared to the previous year. Key financial metrics showed a 35% growth in net sales, reaching $113.7 million, with a notable rise in both wound and surgical product sales. The company’s gross profit margin improved to 83.5%, driven by favorable production variances and product mix. Looking ahead, MiMedx Group remains focused on expanding its product portfolio and navigating potential changes in reimbursement policies, aiming to sustain its growth trajectory in the healthcare market.

MiMedx Group Reports Record Q3 2025 Revenue Growth

MiMedx Group reported a record revenue of $114 million for the third quarter of 2025, marking a 35% increase from the previous year, driven by significant growth in its Wound and Surgical franchises. The company is preparing for potential changes in Medicare and Medicaid reimbursement rules, which it believes will stabilize the industry and benefit stakeholders, while maintaining a positive long-term outlook.

The most recent analyst rating on (MDXG) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

MiMedx Group Joins Cantor Global Healthcare Conference

MiMedx Group announced its participation in the Cantor Global Healthcare Conference on September 3, 2025, and updated its investor presentation. The company is poised to expand its market presence with a focus on growth outside the U.S., increased funding for research, and an expanded product portfolio. The announcement highlights MiMedx’s strategic priorities, including product diversification and enhancing customer intimacy, which are expected to drive growth and profitability. The company also emphasizes its commitment to advocating for Medicare spending reform and leveraging favorable market trends to boost its financial performance.

The most recent analyst rating on (MDXG) stock is a Buy with a $8.50 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.